Peter Probst Email & Phone Number

Houston, Texas, Us

•Responsible for antibody discovery, preclinical and translational development of cancer immunotherapy targets modulating the tumor microenvironment and anti-cancer immune responses; achieved first in patient dosing for a First-in-Class mAb program in Q3, 2021 and a Best-in-Class mAb program in Q4, 2023. •Delivered two additional drug development candidates to CMC and incepted a novel T cell engager program for cancer immunotherapy.•Managed and mentored a team of 9 Ph.D. and non-Ph.D. scientists (Research Associate to Director level); increased in vitro/in vivo capabilities and productivity of group to characterize antibodies from hit to lead to clinical development including mAb screening, functional assay, in vivo validation, PK profile assessment, FC-mediated antibody function, ADA and receptor occupancy assays.•Pharmacological and translational medicine liaison writing and reviewing IND-briefing documents, IND-filing modules; Member of clinical core team supporting clinical trial design and patient sample evaluation for PK/PD, receptor occupancy/target engagement and biomarker identification.

Houston, Texas, Us

See above

Seattle, Wa, Us

Seattle, Wa, Us

•Scientific co-founder of Kineta Immune-Oncology LLC, built immuno-oncology in vitro and in vivo group to discover and develop immunogenic cell death inducing small molecule RIG-I agonist for cancer immunotherapies; developed project plan for I/O collaboration with pharmaceutical partner; program was licensed to pharmaceutical partner 3 years after inception•Led HTS discovery and SAR program to identify small molecule immune modulators targeting IRF pathways; collaborated with medicinal chemistry to optimize small molecule leads.•Immunology/translational lead on autoimmunity and neuro-inflammation biologic programs; developed novel therapeutic concept for autoimmune program in early clinical development (Phase I/II) targeting pathogenic T cells•Responsible for preclinical development of novel H5N1 influenza vaccine adjuvant•Scientific lead on academic collaborations•Principal Investigator on NCI funded Phase 1 and Phase 2 SBIR grants

Expertise and services:• Drug discovery and preclinical development of immunomodulatory/regulatory small molecule and biologics programs• Vaccine discovery and development• Identification of novel opportunities, due diligence and project risk assessment• Generation and evaluation of client data packages• Assay development• Literature searches

Jersey City, New Jersey, Us

• Built immunological capabilities and led immunology team• Characterized novel class of immune response modifiers to treat chronic viral infections and cancer• Performed translational studies for mechanism of action and biomarker assessment• Managed CRO and external collaborations to generate proof of concept data in animal models • Identified novel opportunities for immunomodulatory compounds targeting chronic infectious diseases and cancer• Provided immunological expertise to internal projects, external collaborations and BD opportunities

Seattle, Wa, Us

•Alliance management for external autoimmune and inflammatory disease collaborations•Project leader for early target discovery and lead therapeutic programs •Established in vitro pharmacology group to discover and develop biologic modalities targeting autoimmune or chronically activated T cells for the treatment of autoimmune and inflammatory diseases (A&I)•Successfully developed and executed functional assays focusing on human and murine primary cells to translate viral immune evasion strategies into therapeutic concepts for A&I indications•Collaborated with genetic and bioinformatic colleagues to integrate functional assay data into a biological systems approach to identify targets for A&I •Identified novel mechanism of action for lead therapeutic program which enabled therapeutic concept validation and selection of autoimmune disease indications •Established research objectives and therapeutic concepts for over 20 targets•Developed PK, PD and immunogenicity assays supporting regulatory activities•Provided scientific and competitive intelligence advice for BD activities •Immunology subject matter expert in regulatory/clinical working group•Scientific and technical support for target discovery, therapeutic design, and preclinical in vivo group

•Principal Investigator, Project Leader for NIH contract: ‘Innate Immune Receptors and Adjuvant Discovery’; characterization of synthetic TLR4 agonist/antagonist for monotherapy indications and as vaccine adjuvants•Project Leader for antigen discovery and preclinical development of Chlamydia trachomatis vaccine; Successfully transitioned program to pharmaceutical partner 5 years after initiation; responsible for the preclinical development of a Chlamydia vaccine including inception of vaccine concept, vaccine discovery by T cell expression, lead selection.•Characterized the effects of synthetic TLR4 agonists/antagonists and microbial immunomodulatory proteins on human monocytes, macrophages, and dendritic cells

• Established program to characterize effects of microbial immunomodulatory proteins on human macrophages and dendritic cells

Research Fellowship provided by the Deutsche Forschungsgemeinschaft (German Research Association) to perform research at the Infectious Disease Research Institute (Seattle, Washington)•Generated human leishmanial antigen-specific T cell lines by infecting dendritic cells with Leishmania major •Identified and characterized leishmanial vaccine candidates by human T cell expression cloning.•Characterized the immunomodulatory effects of leishmanial proteins on human primary immune cells